Biosyent Inc (BIOYF) 6.0800 $BIOYF
BioSyent Releases Q1 2016 Results
Marketwire Canada - Fri May 27, 7:01AM CDT
TORONTO, ONTARIO--(Marketwired - May 27, 2016) - BioSyent Inc. ("BioSyent"
(TSX VENTURE:RX) released today a summary of its financial results for the three months ending March 31, 2016. Key highlights include:
RX.VN: 7.940 (+0.030)
FeraMAX(R) Named #1 by Canadian Doctors and Pharmacists
Marketwire Canada - Thu May 26, 7:01AM CDT
TORONTO, ONTARIO--(Marketwired - May 26, 2016) - BioSyent Inc. ("BioSyent" (TSX VENTURE:RX) is pleased to announce that its FeraMAX® brand was recently named as the #1 recommended over-the-counter ("OTC" iron supplement brand in a national survey of Canadian physicians and pharmacists.
RX.VN: 7.940 (+0.030)
IIROC Trade Resumption - BioSyent Inc.
Newsfile Corp - Wed May 25, 12:00PM CDT
Trading resumes in:
BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular Products
Marketwire Canada - Wed May 25, 11:54AM CDT
TORONTO, ONTARIO--(Marketwired - May 25, 2016) - BioSyent Inc. ("BioSyent" (TSX VENTURE:RX) is pleased to announce that its subsidiary BioSyent Pharma International Inc. has signed an exclusive Distribution Agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. BioSyent intends to submit the dossier seeking marketing approval of the products to Health Canada in 2016.
RX.VN: 7.940 (+0.030)
IIROC Trade Halt - BioSyent Inc.
Newsfile Corp - Wed May 25, 11:48AM CDT
The following issues have been halted by IIROC:
BioSyent Schedules Q1 2016 Earnings Release for May 27, 2016
Marketwire Canada - Wed May 25, 9:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 25, 2016) - BioSyent Inc. ("BioSyent" (TSX VENTURE:RX) will be reporting its financial results for the three months ending March 31, 2016 on Friday, May 27, 2016 at 8:00am (EST). A presentation on the Company's first quarter 2016 results by Mr. René Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
RX.VN: 7.940 (+0.030)
BioSyent Pharma Receives Health Canada Approval for New Urgent Care Product Using the Aguettant System(R)
Marketwired - Thu May 05, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 5, 2016) - BioSyent Inc. ("BioSyent" (TSX VENTURE:RX)(OTC PINK:BIOYF) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received approval from Health Canada for a new urgent care product, phenylephrine hydrochloride injection in the Aguettant System® pre-filled syringe (PFS), for use in hospitals and acute care settings.
RX.VN: 7.940 (+0.030)
BioSyent to Present at Upcoming Investor Conferences
Marketwired - Wed Apr 06, 1:08PM CDT
BioSyent Inc. ("BioSyent"(TSX VENTURE: RX)(OTC PINK: BIOYF) is pleased to announce that it will be presenting at the following upcoming investor conferences:
RX.VN: 7.940 (+0.030)
BioSyent Releases Q4 and Full Year 2015 Results
Marketwired - Fri Mar 04, 7:01AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX)(OTC PINK: BIOYF) released today a summary of its financial results for the three and twelve months ending December 31, 2015. Key highlights include:
RX.VN: 7.940 (+0.030)
BioSyent to Present at the LD Micro Main Event 2015 Investor Conference
Marketwired - Mon Nov 30, 8:57AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the LD Micro Main Event 2015 Investor Conference at 9am (PT) on December 3, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Mr. Goehrum will provide an overview of the Company and its corporate activities.
RX.VN: 7.940 (+0.030)
BioSyent Pharma Announces the Canadian Launch of CYSVIEW(R) (Hexaminolevulinate Hydrochloride)
Marketwired - Tue Nov 17, 7:04AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of CYSVIEW(R), a new photosensitizer for the detection and management of papillary Non-Muscle Invasive Bladder Cancer (NMIBC).
RX.VN: 7.940 (+0.030)
BioSyent Releases Q1 2016 Results
Marketwire Canada - Fri May 27, 7:01AM CDT
TORONTO, ONTARIO--(Marketwired - May 27, 2016) - BioSyent Inc. ("BioSyent"
(TSX VENTURE:RX) released today a summary of its financial results for the three months ending March 31, 2016. Key highlights include: RX.VN: 7.940 (+0.030)
FeraMAX(R) Named #1 by Canadian Doctors and Pharmacists
Marketwire Canada - Thu May 26, 7:01AM CDT
TORONTO, ONTARIO--(Marketwired - May 26, 2016) - BioSyent Inc. ("BioSyent"
(TSX VENTURE:RX) is pleased to announce that its FeraMAX® brand was recently named as the #1 recommended over-the-counter ("OTC" iron supplement brand in a national survey of Canadian physicians and pharmacists. RX.VN: 7.940 (+0.030)
IIROC Trade Resumption - BioSyent Inc.
Newsfile Corp - Wed May 25, 12:00PM CDT
Trading resumes in:
BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular Products
Marketwire Canada - Wed May 25, 11:54AM CDT
TORONTO, ONTARIO--(Marketwired - May 25, 2016) - BioSyent Inc. ("BioSyent"
(TSX VENTURE:RX) is pleased to announce that its subsidiary BioSyent Pharma International Inc. has signed an exclusive Distribution Agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. BioSyent intends to submit the dossier seeking marketing approval of the products to Health Canada in 2016. RX.VN: 7.940 (+0.030)
IIROC Trade Halt - BioSyent Inc.
Newsfile Corp - Wed May 25, 11:48AM CDT
The following issues have been halted by IIROC:
BioSyent Schedules Q1 2016 Earnings Release for May 27, 2016
Marketwire Canada - Wed May 25, 9:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 25, 2016) - BioSyent Inc. ("BioSyent"
(TSX VENTURE:RX) will be reporting its financial results for the three months ending March 31, 2016 on Friday, May 27, 2016 at 8:00am (EST). A presentation on the Company's first quarter 2016 results by Mr. René Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release. RX.VN: 7.940 (+0.030)
BioSyent Pharma Receives Health Canada Approval for New Urgent Care Product Using the Aguettant System(R)
Marketwired - Thu May 05, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 5, 2016) - BioSyent Inc. ("BioSyent"
(TSX VENTURE:RX)(OTC PINK:BIOYF) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received approval from Health Canada for a new urgent care product, phenylephrine hydrochloride injection in the Aguettant System® pre-filled syringe (PFS), for use in hospitals and acute care settings. RX.VN: 7.940 (+0.030)
BioSyent to Present at Upcoming Investor Conferences
Marketwired - Wed Apr 06, 1:08PM CDT
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX)(OTC PINK: BIOYF) is pleased to announce that it will be presenting at the following upcoming investor conferences: RX.VN: 7.940 (+0.030)
BioSyent Releases Q4 and Full Year 2015 Results
Marketwired - Fri Mar 04, 7:01AM CST
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX)(OTC PINK: BIOYF) released today a summary of its financial results for the three and twelve months ending December 31, 2015. Key highlights include: RX.VN: 7.940 (+0.030)
BioSyent to Present at the LD Micro Main Event 2015 Investor Conference
Marketwired - Mon Nov 30, 8:57AM CST
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the LD Micro Main Event 2015 Investor Conference at 9am (PT) on December 3, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Mr. Goehrum will provide an overview of the Company and its corporate activities. RX.VN: 7.940 (+0.030)
BioSyent Pharma Announces the Canadian Launch of CYSVIEW(R) (Hexaminolevulinate Hydrochloride)
Marketwired - Tue Nov 17, 7:04AM CST
BioSyent Inc. ("BioSyent"
(TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of CYSVIEW(R), a new photosensitizer for the detection and management of papillary Non-Muscle Invasive Bladder Cancer (NMIBC). RX.VN: 7.940 (+0.030)
